Acorda stock: buy or sell?
January 24th, 2020
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.
Should I buy Acorda stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Acorda stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Acorda Therapeutics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 7 ratings published for ACOR stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-5-7||JPMorgan Chase & Co.||n/a||Hold|
Acorda stock analysis
After boosting an extraordinary 12.66% on January/23, Acorda Therapeutics closed yesterday at $2.10 and plummed a dreadful -11.39%.
After boosting an extraordinary 12.66% on January 23rd, Acorda Therapeutics closed yesterday at $2.10 and plummed a dreadful -11.39%. In this session, Acorda Therapeutics stock crossed down the SMA100d line. If you are using SMA100d line as stop loss trigger, double check your position in this stock.
After sliding a bloodcurdling -14.01% in a week last week, Acorda closed this week at $2.10 and inched a decent 1.45%. Late December 2019 ACOR skyrocketed a dazzling 32.06% in just one week.
ACOR shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $1.82 last week. Previous top ($2.78) will play as a resistance in possible new gains. Since last week, when ACOR stock price broke down the 20-weeks moving avarage line, it slid $-0.26 per share (-11.02%).
Acorda stock price history
Acorda stock went public on February 10th, 2006 with a price of $6.171. Since then, ACOR stock lost a -66.00%, with a yearly average of -5.10%.
1: Adjusted price after possible price splits or reverse-splits.
Acorda stock historical price chart
ACOR stock reached 52-week highs on January at $17.41, and all-time highs 2015-01-13 with a price of 45.45.
Acorda stock price target is $11.00How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 7 price targets for Acorda Therapeutics stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-2||Stifel Nicolaus||Lowers Target||$12.00||$7.00||-41.7%|
|2019-8-2||Cantor Fitzgerald||Lowers Target||$20.00||$12.00||-40%|
|2019-5-7||JPMorgan Chase & Co.||Reiterates||n/a||$18.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince February, when Acorda Therapeutics presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a scary correction of -19.86% to $471.43 million dollars. When comparing 2018 vs 2017, improving that, profit margin (that is, the net income divided by revenues) rocketed a 45.11% to 7.14%.
|2013||$336 M||-||$16 M4.9%||-|
|2014||$401 M||19.34%||$18 M4.4%||7.49%|
|2015||$493 M||22.71%||$11 M2.2%||-37.43%|
|2016||$520 M||5.47%||$-34.62 M-6.7%||-413.06%|
|2017||$588 M||13.22%||$-223.36 M-38.0%||545.21%|
|2018||$471 M||-19.86%||$34 M7.1%||-115.08%|
Quarterly financial resultsAcorda Therapeutics posted $69.15 M in revenues for 2018-Q4, a -51.58% decline compared to previous quarter. Reported quarter income marked $9.60 million with a profit margin of 13.88%. Profit margin boosted a 23.62% compared to previous quarter when profit margin was -9.74%. When comparing sales to same quarter last year, Acorda sales marked a hair-raising slide and collapsed a -63.29%. Looking back to recent quarterly results, Acorda Therapeutics posted 2 positive quarters in a row.
|2017-Q1||$119 M||-||$-19 M-15.8%||-|
|2017-Q2||$139 M||16.79%||$-8 M-5.9%||-56.61%|
|2017-Q3||$141 M||1.17%||$-25 M-17.9%||207.26%|
|2017-Q4||$188 M||33.55%||$-171 M-90.8%||578.96%|
|2018-Q1||$106 M||-43.65%||$-8 M-7.7%||-95.21%|
|2018-Q2||$153 M||44.40%||$46 M30.1%||-663.45%|
|2018-Q3||$143 M||-6.84%||$-14 M-9.7%||-130.11%|
|2018-Q4||$69 M||-51.58%||$10 M13.9%||-168.97%|
Acorda ownershipWhen you are planning to invest in shares of a company, it's worth to overview its ownership structure.
Acorda shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.49% of all shares.
Bearish positions for ACOR stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Acorda:
|Market cap||$100.9 M|
|Total shares||48.0 M|
|Float shares||43.1 M|
|- Institutional holdings (%)||118.9%|
|- Insider holdings (%)||1.5%|
|Shares in short selling||0.0%|
|Friday, January 24th, 2020|
|Day range||$2.10 - $2.48|
|Average true range||$0.27|
|50d mov avg||$1.96|
|100d mov avg||$2.37|
|200d mov avg||$5.07|
Acorda performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Acorda Therapeutics performance to :